Le côlon des mammifères est colonisé d'environ 1013 bactéries. Si ce microbiote contribue au métabolisme, au développement et à la protection de l'organisme et représente une source massive d'antigènes. Il doit donc être compartimenté afin d'empêcher leur dissémination dans l'organisme où il pourrait être délétère. Lors de ma thèse, je me suis intéressé au rôle du Transforming Growth Factor beta (TGF-bêta, une cytokine fortement exprimée sous forme inactive au niveau de l'intestin des mammifères. Nous avons pu montrer que l'expression de l'intégrine alphav bêta 8par les lymphocytes T régulateurs (Treg) est essentielle à l'activation du TGF-bêta. Par ailleurs, mes travaux démontrent que deux protéines de la voie de signalisation du TGF-bêta, TIF-1gamma et SMAD4, contrôlent l'expression de l'IL-22 dans les cellules lymphocytaires innées de groupe 3 (ILC3) du côlon, responsable du maintien l'intégrité de la barrière intestinale empêchant l'entrée massive de bactéries et une suractivation des lymphocytes Th17 impliqués dans le développement spontané de cancers colorectaux. Ainsi, mes travaux de recherche ont permis de mettre en évidence le rôle clé du TGF-bêta dans le maintien de l'intégrité intestinale essentiel à la prévention du développement de cancers colorectaux induits spontanément par le microbiote / Mammalian colon harbors about 1013 bacteria. Although this microbiota contributes to metabolism, development and protection of the organism, it constitutes a huge source of antigens and must be compartmentalized in order to prevent intestinal bacteria dissemination in the organism that could be harmful for the host. During my PhD, I was interested in the role of Transforming Growth Factor beta (TGF-beta, a highly expressed cytokine and produced as an inactive form in mammalian gut. We showed that the expression of integrin alpha v beta 8by regulatory T cells (Treg) is essential to activate TGF-beta. Moreover, my work revealed that two proteins of the TGF-beta signaling pathway, TIF-1gamma and SMAD4, are responsible for the control of the expression of IL-22 within colonic group 3 Innate Lymphoid Cells (ILC3) which maintains the intestinal barrier integrity and prevents bacteria from entering and over-activation of Th17 cells involved in spontaneous colorectal cancer development. My work revealed a key role for TGF-beta in the maintenance of intestinal barrier-integrity essential to prevent spontaneous microbiota-induced colorectal cancer development

Le cancer du sein est une maladie impactant le système immunitaire dont le rôle évolue au cours de la tumorigénèse, allant de la détection et l'élimination des cellules transformées (immunosurveillance) à la promotion du développement tumoral (immunosubversion). Les efforts déployés pour définir de nouvelles stratégies thérapeutiques ont révélé que rétablir l'immunité anti-tumorale chez les patientes permettrait d'améliorer leur pronostic. Durant ma thèse, nous avons mis en évidence l'existence de signaux activateurs et inhibateurs des pDC dans les cancers du sein, qui confèrent aux pDC un rôle dans l'immunosurveillance et dans l'échappement immunitaire du cancer du sein respectivement. Nous avons ainsi montré que le TGF-beta et le TNF-alpha sont impliqués dans l'inhibition fonctionnelle des TApDC en réprimant l'expression et l'activation d'IRF-7. Dans un second temps, nous avons montré i) la présence de complexes [ADN-LL37] produits par les neutrophiles dans les tumeurs et capables d'induire la production d'IFN-alpha par les pDC, ii) l'expression des gènes associés aux IFN-I dans les tumeurs de sein et iii) un rôle majeur de la voie des IFN-I dans l'immunosurveillance des tumeurs mammaires chez la souris. De plus, des données préliminaires chez la souris suggèrent que les pDC participent à l'immunosurveillance anti-tumorale in vivo. Les travaux présentés dans ce manuscrit apportent de nouvelles données sur le rôle des pDC dans l'immunosurveillance des cancers du sein et ouvrent sur de nouvelles stratégies d'immunothérapie anti-tumorale ciblant les pDC / Breast cancer are disease impacting immune system whose play role during tumorigenesis, to detect and eliminate malign cells (immunosurveillance) or promote tumoral development (immunosubversion). Efforts to define new therapeutic strategies revealed that restoring anti-tumor immunity in patients would improve their prognosis. During my thesis, first, we demonstrated the existence of stimulatory and inhibitory signals of pDCs in the breast, which give the pDCs a role in immunosurveillance and immune escape of breast cancer, respectively. We showed that TGF-beta and TNF-alpha are involved in the functional inhibition of TApDC repressing IRF-7 expression and activation. Secondly, we showed i) the presence of [DNA LL37] complex produced by neutrophils in tumors that can induce the production of IFN-alpha by pDCs, ii) the expression of type I IFN associated genes in breast tumors and iii) a major role of IFN-I pathway in immunosurveillance of mammary tumors in mice. In addition, in mice, preliminary data suggest that pDC could play a role in anti-tumor immunosurveillance in vivo. The work presented in this thesis provide new data on the role of pDCs in immunosurveillance of breast cancers, and open new anti-tumor immunotherapy strategies targeting pDCs

Arkadia participa do processo de amplificação da sinalização de TGF-b mediada por Smads, via degradação do I-Smad. O objetivo desse estudo foi caracterizar e investigar a influência de Arkadia em linhagens celulares de cânceres de tiróide. A expressão gênica de Arkadia em linhagens celulares de carcinomas papílifero (NPA), folicular (WRO) e anaplásico (ARO), foi avaliada por PCR quantitativo. Em ARO, que apresenta a maior expressão de Arkadia, foram identificados subclones (ARO_1 e ARO_2) com expressão diferencial de Arkadia, ARO_2>ARO_1. A expressão gênica de SMAD2, 3, 4, 7 e de genes do ciclo celular modulados por TGF-b, foi maior em ARO_2. Os subclones respondem ao tratamento com peptídeo de TGF-b1 e activina A. O crescimento in vivo (xenotransplante) mostra que ARO_2 desenvolve um tumor de menor volume. Recentemente a origem de ARO foi questionada e comprovamos sua origem por análises de expressão gênica e morfologias. Desta maneira, observamos que a expressão diferencial de Arkadia indica que ela está envolvida na modulação inibitória da via de TGF-b. / Arkadia is involved in the process of amplification of the TGF-b signaling mediated by Smads, by degradation of I-Smad. The aim of this study was to characterize and investigate the influence of Arkadia in thyroid cancers cell lines. Arkadia gene expression in the papillary (NPA), follicular (WRO) and anaplastic carcinoma cell lines (ARO) was evaluated by quantitative PCR. In ARO, which presents the highest Arkadia expression, we identified subclones (ARO_1 and ARO_2) with differential Arkadia expression ARO_2> ARO_1. The expression of SMAD2, 3, 4, 7 and the cell cycle genes modulated by TGF-b, was also higher in ARO_2. However both the subclones responded to treatment with peptide of TGF-b1 and activin A. The in vivo growth (evaluated by xenotransplant), showed that ARO_2 developed tumors of lower volume. Recently the ARO origin was questioned and we proved its origin by gene expression and morphological analysis. This way, the differential Arkadia expression indicates that it is involved in modulation of the inhibitory TGF-b pathway.

A causa de morte da maioria das pacientes com câncer de mama se deve à doença metastática desenvolvida a partir do tumor primário. A degradação dos componentes da matriz extracelular (MEC), um dos principais eventos do processo metastático, é regulada pelo balanço entre as atividades das metaloproteinases de matriz (MMPs) e dos seus inibidores, tanto os inibidores teciduais (TIMPs) como o inibidor associado à membrana (RECK). Contudo, ainda existe pouca informação sobre os mecanismos moleculares responsáveis pela manutenção deste balanço. No presente trabalho, foi investigado o envolvimento de TGF-β1 (Transforming Growth Factor-β1), uma citocina multifuncional é capaz tanto de inibir o crescimento celular, quanto de promover invasão e metástase, dependendo do estadiamento e do tipo de tumor, na regulação da expressão de MMPs, TIMPs e RECK, em modelo de câncer de mama. Primeiramente, examinou-se os níveis de expressão de mRNA das isoformas e receptores de TGF-β, em um painel de cinco linhagens de carcinoma mamário humano, com diferentes potenciais invasivos e metastáticos, por qRT-PCR. Os resultados obtidos demonstraram uma correlação positiva entre a expressão dessas moléculas, e a progressão do caráter invasivo e metastático celular. Em seguida, a linhagem altamente invasiva, MDA-MB-231, foi tratada com diferentes concentrações de TGF-β1 recombinante. Esta citocina foi capaz de modular a expressão gênica de MMPs (MMP-2 e MMP-9) e de seus inibidores (TIMP- 2 e RECK). Tanto ERK½, quanto p38MAPK mostraram-se envolvidas neste mecanismo. Foi demonstrado que a inibição da atividade de ERK½ alterou a expressão das proteínas MMP-9, TIMP-2 e RECK, enquanto o bloqueio de p38 MAPK afetou os níveis protéicos de MMP-2 e TIMP-2. O aumento do potencial migratório e invasivo da linhagem MDA-MB-231, induzido por TGF-β1, mostrou-se também dependente da atividade de MMPs, ERK½ e p38MAPK. Dada a ausência de informações sobre o papel de RECK em modelo mamário, a função deste inibidor de MMPs também foi investigada. Primeiramente, analisou-se a expressão de RECK ao longo do desenvolvimento da mama e, posteriormente, em 1040 amostras tumorais de mama humana, através da metodologia de Tissue Microarray, tendo sido possível demonstrar que a alta expressão de RECK associa-se a menor tempo de sobrevida global e livre de doença em 10 anos. Os resultados obtidos indicaram que a expressão da proteína RECK, em oposição ao verificado em outros tipos de tumores, está relacionada ao fenótipo mais agressivo de tumores de mama. Entretanto, a análise funcional de RECK, realizada por meio da utilização de vetores shRNA específicos para a inibição desta proteína, demonstrou que RECK também atua como um inibidor de invasão celular e da expressão de MMP-9, na linhagem MDA-MB-231. Em conjunto, os resultados obtidos neste trabalho contribuíram para a elucidação dos mecanismos moleculares de regulação de RECK, por clássicas moléculas associadas ao processo de tumorigênese (TGF-β1 e MAPKs), bem como para o esclarecimento de suas funções em modelo mamário, sugerindo-o como mais um promissor candidato a marcador prognóstico e alvo molecular para a terapia do câncer de mama. / The metastatic disease is the main mortality cause of breast cancer patients. The metastatic process involves a complex cascade of events, including the organized breakdown of the extracellular matrix (ECM) compounds. The degradation of ECM is tightly regulated by the balance between the activities of matrix metalloproteinases (MMPs) and their inhibitors, the tissue inhibitors (TIMPs) and the membrane-associated inhibitor (RECK). Among the several molecules released and activated by ECM remodeling, TGF-β1 (Transforming Growth Factor-β1) is a multifunctional cytokine able to regulate both cell growth inhibition and invasion and metastasis promotion, depending on the tumor stage and type. Since the molecular mechanisms involved in the ECM remodeling control are still not completed understood, in this study, we investigated the involvement of TGF-β1 in regulating of MMPs, TIMPs and RECK expression, in the breast cancer model. By qRT-PCR, we first examined the gene expression levels of TGF-β isoforms and receptors, in a panel of five human breast cancer cell lines displaying different degrees of invasiveness and metastatic potential. Our results suggest a positive correlation between the mRNA expression of these molecules and the breast cancer progression. Moreover, the highly invasive breast cancer cell line MDA-MB-231 was treated with different concentrations of recombinant TGF-β1. We described that this cytokine was able to modulate the gene expression of MMPs (MMP-2 and MMP-9) and MMPs inhibitors (TIMP-2 and RECK) at both the mRNA and protein levels, with ERK½ and p38 MAPK being involved in this molecular mechanism. However, while ERK½ activity inhibition altered MMP-9, TIMP-2 and RECK expression, the p38 MAPK blockage affected the protein levels of MMP-2 and TIMP-2. Finally, we reposted that the TGF-β1-enhanced migration and invasion capacities of MDA-MB- 231 cells were blocked by MMPs, ERK½ and p38 MAPK inhibitors. Analysis of the RECK function in the breast model was also an objective of this study. We analyzed RECK expression during mammary gland development. We evaluated the RECK protein profile in 1040 breast tumor tissue samples using Tissue Microarray assays. We demonstrated that high expression levels of RECK were associated with shorter overall and disease-free survival in 10 years. Moreover, we verified that RECK is a biomarker of poor prognosis mainly for patients diagnosed with less aggressive breast tumor. Therefore, in contrast to other tumor types, our results indicate that high protein expression levels of RECK are related to a more aggressive phenotype. In fact, the RECK functional analysis, performed by using of shRNA vectors, showed that RECK function remains as an inhibitor of cellular invasion and MMP-9 expression, in MDA-MB-231 cells. Taken together, our results contribute to better understanding of the molecular mechanisms associated to RECK regulation by TGF-β1 and MAPK as well as to clarify its role in breast model. Thus, we suggests RECK as a new and promising prognostic marker and molecular target candidate for breast cancer therapy.

Zirkadiane Uhren sind Zell-autonome Oszillatoren. Aus diesem Grund ist deren interzelluläre Kopplung essentiell, um die Synchronität zirkadianer Oszillatornetzwerke zu erhalten und die Störung zirkadianer Gewebsfunktionen zu verhindern. Neuronale Oszillatoren des Nucleus suprachiasmaticus (SCN), der Schrittmacher-Uhr im Zentralnervensystem der Säugetiere, koppeln interzellulär und über den Austausch sekretierter Neurotransmitter. Die Fähigkeit zirkadianen Oszillatoren peripherer Gewebe interzellulär zu koppeln ist hingegen stark umstritten und molekulare Mechanismen sind unbekannt. In dieser Dissertation zeigen wir, dass periphere Oszillatoren in der Tat interzellulär über den Austausch sekretierter Signalmoleküle koppeln und identifizieren TGF-b als peripheren Kopplungsfaktor. Weiterhin zeigen wir, dass TGF-b die cAMP Enhancer-Motiv abhängige, als auch Immediate Early Expression des Uhr-Gens PER2 induziert und folglich die Phasenanpassung molekularer zirkadianer Oszillationen reguliert. Genetische und pharmakologische Störeinflüsse verursachen die Dysregulation des TGF-b Signalweges und begünstigen die Desynchronisierung zellulärer Oszillatoren, welche sich in Amplitudenreduktion und verstärkter Sensitivität gegenüber Zeitgeber-Signalen äußert. Die in dieser Dissertation präsentierten Ergebnisse, legen einen bisher unbekannten molekularen Mechanismus intrazellulärer Kopplung peripherer zirkadianer Oszillatoren dar und eröffnen neue Perspektiven auf die Bedeutung der Synchronität peripher zirkadianer Uhren für rhythmische Organfunktionen und zirkadiane Gesundheit. / Circadian clocks are cell-autonomous oscillators. Intercellular coupling is crucial to prevent desynchronization of oscillator networks and thus, the disruption of circadian tissue functions. While neuronal oscillators within the mammalian central clock, the suprachiasmatic nucleus (SCN), couple intercellularly via the exchange of secreted neurotransmitters, intercellular coupling among peripheral oscillators is highly debated and molecular mechanisms are unknown. Here, we show that peripheral circadian oscillators couple intercellularly via exchange of secreted signaling molecules and identify TGF-ß as peripheral coupling factor. TGF-ß signaling induces the cAMP response element dependent, immediate-early expression of the clock gene PER2, thereby phase-adjusting the molecular circadian oscillator. Genetic or pharmacologic disruption of TGF-ß signaling causes desynchronization of cellular oscillators resulting in amplitude reduction and increased sensitivity towards Zeitgeber cues. Our findings reveal a previously unknown mechanism of peripheral coupling and open new perspectives on the importance of peripheral clock synchrony for rhythmic organ functions and circadian health.

Durch Analyse der Subtraktion-cDNA Bibliothek einer humanen Lungentumor Zelllinie haben wir ein neues Mitglied der S100 Genfamilie identifiziert und charakterisiert, welches S100A14 benannt wurde. Die vollständige cDNA hat eine Länge von 1067 bp und kodiert für ein Protein von 104 Aminosäuren, welches die S100-spezifische Kalzium-bindende Domäne enthält. Das Gen wird in normalen humanen Epithelien ubiquitär exprimiert, zeigt jedoch Expressionsverluste in vielen Tumorzelllinien. Im Gegensatz zu Tumorzelllinien ist S100A14 auf mRNA- und Proteinebene in vielen humanen Primärtumoren stärker exprimiert, unter anderem in Lungen- und Brustkarzinomen. Um den Mechanismus der erhöhten S100A14 Expression in Lungen- und Brustkarzinomen zu verstehen, haben wir die Effekte des EGF (epidermal growth factor) und des TGF-alpha (transforming growth factor-alpha) untersucht. Beide Faktoren sind Liganden des ERBB Rezeptors und induzieren in der immortalisierten bronchialen Epithelzelllinie S100A14 Expression. Unter Verwendung spezifischer Inhibitoren konnte gezeigt werden, dass für die EGF-vermittelte transkriptionelle Induktion der ERK1/2 Signalweg (extracellular signal-regulated kinase) verantwortlich ist und eine de novo Proteinsynthese erfordert. Diese Ergebnisse unterstützend konnte immunhistologisch eine signifikante Korrelation zwischen der Überexpression von ERBB2 und S100A14 in primären Brustkarzinomen nachgewiesen werden. Phorbolester-12-Myristat-13-Acetat (PMA) verstärkte gleichfalls die S100A14 mRNA Expression in 9442 Zellen, was eine Regulation durch die Protein Kinase C (PKC) vermuten lässt. Die PMA-induzierte Expression von S100A14 wird ebenso wie die TGF-alpha/EGF-Induktion durch die Aktivierung des ERK1/2 Signalweges vermittelt. In Anbetracht der großen Bedeutung der ERK1/2 und PKC Signalwege in der Tumorentstehung und Tumorprogression ist zu vermuten, dass S100A14 über die aberrante Regulation dieser Signalwege an die maligne Transformation gekoppelt ist. / By analysing a human lung tumour cell line subtraction cDNA library, we have identified and characterized a novel member of the human S100 gene family that we designated S100A14. The full-length cDNA is 1067 bp and encodes a putative protein of 104 amino acids. The predicted protein contains the S100-specific EF-hand calcium-binding domain. The gene is ubiquitously expressed in normal human tissues of epithelial origin. S100A14 transcript was found to be down-regulated in many immortalized and tumour cell lines from diverse tissues. In contrast to the tumour cell lines, S100A14 shows up-regulation at the mRNA and protein level in many human primary tumours, including lung and breast carcinomas. To elucidate mechanisms whereby S100A14 expression is enhanced in lung and breast tumours, we studied the effects of epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-alpha) on its expression. Both are ligands of ERBB receptor and induced S100A14 expression in the immortalized bronchial epithelial cells. By use of specific inhibitors, we found that EGF-mediated transcriptional induction of S100A14 involves extracellular signal-regulated kinase (ERK1/2) signalling and requires de novo protein synthesis. In support of these findings, we demonstrated by immunohistochemistry a significant correlation between ERBB2 and S100A14 protein overexpression in primary breast carcinomas. Our studies showed that the phorbol ester 12-myristate 13-acetate (PMA) increases S100A14 mRNA expression in immortalized bronchial epithelial cells suggesting regulation by protein kinase C (PKC). Similar to TGF-alpha/EGF induction, the PMA-induced S100A14 expression was also mediated by activation of the ERK1/2 signalling cascade. Considering the importance of the ERK1/2 and PKC signalling pathways in tumour development and progression we suggest that it is the aberrant regulation of these signalling cascades that couples S100A14 to malignant transformation.

Der Skelettmuskel ist ein dynamisches Gewebe, das seine Funktionalität durch Anpassung des Gleichgewichts zwischen Proteinabbau und Proteinsynthese aufrechterhält. Kritisch kranke septische Patienten in der Intensivstation erleiden häufig eine dort erworbene tiefgreifende Muskelschwäche und –atrophie (intensive care unit acquired weakness, ICUAW). Es gibt Hinweise darauf, dass die Regenerationsfähigkeit des Muskels bei kritisch kranken Patienten beeinträchtigt ist. Die Pathogenese der ICUAW ist nur unzureichend verstanden, jedoch werden Sepsis und Entzündungen als führende Risikofaktoren angesehen. In früheren RNA-Sequenzierungsanalysen aus Muskeln septischer Mäuse wurde eine Herunterregulierung des Transforming Growth Factor beta (TGF-β)-Signals und eine erhöhte Genexpression von SPRY domain and SOCS-box containing protein 1 (SPSB1) gefunden. Ich stellte also die Hypothese auf, dass SPSB1 die Proteinhomöostase im Muskel beeinträchtigt, indem es den TGF-β/TβRII-Signalweg beeinflusst und eine entzündungsinduzierte Muskelatrophie verursacht. Die quantitative Echtzeit-Polymerase-Kettenreaktion verifizierte eine erhöhte Spsb1/SPSB1-Expression im Skelettmuskel von septischen Mäusen und ICUAW-Patienten. Die inflammatorischen Zytokine IL-6, IL-1β und Tumor-Nekrose-Faktor induzierten Spsb1 in C2C12-Myozyten in vitro. Die Überexpression von SPSB1 hemmte den TGF-β-Akt-Signalweg durch Destabilisierung von TβRII, was zu einer reduzierten Proteinsynthese in Myozyten führte. Als Konsequenz beeinträchtigte die SPSB1-Überexpression die Myogenese von C2C12-Myoblasten, gemessen an reduzierten Differenzierungs- und Fusionsindizes, sowie einer verminderten Protein- und mRNA-Expression der Differenzierungsfaktoren Mymk, Mymx, Myog, Myh1, 3 und 7. Zusammengenommen hemmt SPSB1 den TβRII-Signalweg im entzündeten Skelettmuskel, was die Myogenese beeinträchtigt. Daher könnte die Hemmung von SPSB1 hilfreich sein, um entzündungsinduziertes Muskelversagen zu verhindern. / Skeletal muscle is a dynamic tissue which maintains its functionality by adapting the balance between protein degradation and protein synthesis. Critically ill septic patients often develop intensive care unit acquired weakness (ICUAW), characterized by profound muscle weakness and atrophy. Emerging evidence suggests that the regenerative ability is impaired in patients with ICUAW. However, the pathogenesis of this disease is poorly understood. Sepsis and inflammation are considered as leading risk factors for ICUAW. In previous RNA sequencing analyses from muscle of septic mice, downregulation of transforming growth factor beta (TGF-β)-signaling and an increased gene expression of SPRY domain and SOCS-box containing protein 1 (SPSB1) have been found. If SPSB1 and TGF-β signaling play a role in inflammation-induced muscle atrophy was unknown. I hypothesized that SPSB1 impairs protein homeostasis in muscle by affecting TGF-β/TβRII signaling and causes inflammation-induced muscle atrophy. Quantitative real-time polymerase chain reaction verified increased Spsb1/SPSB1 expression in skeletal muscle of septic mice and ICUAW patients. The inflammatory cytokines IL-6, IL-1β and tumor necrosis factor induced Spsb1 in C2C12 myocytes in vitro. Overexpression of SPSB1 inhibited the TGF-β-Akt signaling pathway by destabilization of TβRII, leading to reduced protein synthesis in myocytes. These effects on TβRII signaling were mediated by the SPRY- and SOCS-box domains of SPSB1. As a consequence, SPSB1 overexpression impaired myogenesis of C2C12 myoblasts as measured by reduced differentiation and fusion indices, decreased protein and mRNA expression of the differentiation factors Mymk, Mymx, Myog, Myh1, 3 and 7. Taken together, SPSB1 binds and inhibits TβRII signaling in the inflammatory skeletal muscle resulting in impaired myogenesis. Therefore, inhibition of SPSB1 could be useful to prevent inflammation-induced muscle failure.

No description available.

Doctor of Philosophy / Department of Biochemistry / Anna Zolkiewska / ADAMs (a disintegrin and metalloprotease) can influence multiple cellular processes involved in normal development and pathogenesis. ADAM12 expression levels are elevated in many pathological conditions including cancer, cardiovascular disease, and muscle regeneration. Recently, ADAM12 has emerged as a candidate cancer gene in a comprehensive genetic analysis of human breast cancers. The regulation of ADAM12 expression is poorly understood. Identification of new substrates for ADAM12 metalloprotease can expand our knowledge of processes in which ADAM12 is involved. Here, we show that ADAM12 expression is upregulated by transforming growth factor beta (TGF-beta), an essential signaling pathway for many cellular processes. This upregulation requires proteosomal degradation of a transcriptional repressor SnoN. Furthermore, breast cancer cell lines expressing high levels of SnoN have significantly impaired induction of ADAM12 by TGF-beta, suggesting an inverse correlation between SnoN and the extent of regulation of ADAM12 by TGF-beta. Additionally, we demonstrate that ADAM12 is one of the metalloproteases involved in shedding a Notch ligand, Delta like 1 (Dll1). The Notch signaling pathway plays a crucial role in cell fate decision during development and in adults. Cleavage of Dll1 by ADAMs occurs in cis and results in activation of Notch signaling in a cell-autonomous manner. Furthermore, the intracellular domain of Dll1 created after cleavage further enhances TGF-beta signaling in response to TGF-beta. Our analysis of breast cancer-associated mutations in the ADAM12 gene showed a lack of proper proteolytic processing of the ADAM12 protein and its mislocalization to the endoplasmic reticulum. Additionally, ADAM12 mutants show a dominant-negative effect on the processing of the wild-type ADAM12 and result in loss of the functional ADAM12 at the cell surface. Collectively, our results indicate a new mechanism of regulation of ADAM12 expression, expand the role of ADAM12 in the regulation of Notch signaling, and characterize cancer-associated mutations in the ADAM12 gene.

No description available.